menu
    • menu
    [{"orgOrder":0,"company":"Lomond Therapeutics","sponsor":"Yosemite Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Private Placement","leadProduct":"Lomonitinib","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Lomond Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Oral Capsule","sponsorNew":"Lomond Therapeutics \/ Yosemite Capital","highestDevelopmentStatusID":"6","companyTruncated":"Lomond Therapeutics \/ Yosemite Capital"},{"orgOrder":0,"company":"Lomond Therapeutics","sponsor":"Deerfield Management Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Private Placement","leadProduct":"Lomonitinib","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Lomond Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Oral Capsule","sponsorNew":"Lomond Therapeutics \/ Deerfield Management Company","highestDevelopmentStatusID":"6","companyTruncated":"Lomond Therapeutics \/ Deerfield Management Company"},{"orgOrder":0,"company":"Eilean Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lomonitinib","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Eilean Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eilean Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Eilean Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eilean Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lomonitinib","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Eilean Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eilean Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Eilean Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eilean Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Lomonitinib","moa":"FLT3","graph1":"Oncology","graph2":"Phase I","graph3":"Eilean Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eilean Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Eilean Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eilean Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Balamenib","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Eilean Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Eilean Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Eilean Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Lomond Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Lonitoclax","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"Lomond Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lomond Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"Lomond Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Eilean Therapeutics","sponsor":"Expert Systems","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Eiletoclax","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Eilean Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eilean Therapeutics \/ Expert Systems","highestDevelopmentStatusID":"6","companyTruncated":"Eilean Therapeutics \/ Expert Systems"},{"orgOrder":0,"company":"Eilean Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Eiletoclax","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Eilean Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eilean Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Eilean Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Eilean Therapeutics

    Menu

    Eilean Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Lomond Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Lomond Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lomonitinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Yosemite Capital

                            Deal Size : $64.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Lomond Therapeutics Completes Second and Third Closings and Adds Two New Investors

                            Details : The net proceeds from the placement will used to fund the clincial development of ZE46-0134 (lomonitinib), which is being evaluated for the treatment of AML.

                            Product Name : ZE46-0134

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 28, 2025

                            Lead Product(s) : Lomonitinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Yosemite Capital

                            Deal Size : $64.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Lomond Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Lomond Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lomonitinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Deerfield Management Company

                            Deal Size : $44.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            Lomond Therapeutics Completes Reverse Merger and Closes $44 Million Private Placement

                            Details : The net proceeds from the placement will used to fund the clincial development of ZE46-0134 (lomonitinib), which is being evaluated for the treatment of AML.

                            Product Name : ZE46-0134

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            November 04, 2024

                            Lead Product(s) : Lomonitinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Deerfield Management Company

                            Deal Size : $44.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Eilean Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Eilean Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Balamenib

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Eilean Approved to Initiate Trial with Balamenib, a Best-in-Class Menin Inhibitor

                            Details : ZE63-0302 (balamenib) is a selective best-in-class oral small molecule inhibitor of the menin-KMT2A interaction. It is being evaluated for the treatment of hematological malignancies.

                            Product Name : ZE63-0302

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 03, 2024

                            Lead Product(s) : Balamenib

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Lomond Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Lomond Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lonitoclax

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lomond’s Lonitoclax IND Cleared by FDA for Chronic Lymphocytic Leukemia

                            Details : Lonitoclax has a best-in-class potency and selectivity against BCL-2. Currently, it is being evaluated for the treatment of chronic lymphocytic leukemia.

                            Product Name : Undisclosed

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 15, 2024

                            Lead Product(s) : Lonitoclax

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Eilean Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Eilean Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lomonitinib

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Eilean Receives Clearance to Initiate R/R AML Trial with Lomonitinib

                            Details : ZE46-0134 (lomonitinib) is a potent and selective inhibitor of FLT3 ITD, TKD, and other FLT3 mutations, as well as IRAK4, under investigation for relapsed/refractory acute myeloid leukemia.

                            Product Name : ZE46-0134

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            April 04, 2024

                            Lead Product(s) : Lomonitinib

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Eilean Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Eilean Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eiletoclax

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Expert Systems

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Expert Systems Celebrates Fast-Tracked Human Dosing Start for Eiletoclax in Just 3 Years

                            Details : ZE50-0134 (eiletoclax) is a selective BCL2 inhibitor, which is being evaluated for the treatment of chronic lymphocytic leukemia & acute myeloid leukemia.

                            Product Name : ZE50-0134

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 21, 2024

                            Lead Product(s) : Eiletoclax

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Expert Systems

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Eilean Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Eilean Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lomonitinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Eilean Therapeutics Completes Studies and Begins Multiple Dosing Of Lomonitinib

                            Details : ZE46-0134 (lomonitinib) is a potent, selective pan-FLT3/IRAK4 inhibitor currently being tested in phase 1 trials for FLT3-mutated Acute Myeloid Leukemia.

                            Product Name : ZE46-0134

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 29, 2024

                            Lead Product(s) : Lomonitinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Eilean Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Eilean Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eiletoclax

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Eilean Initiates Human Trial for Eiletoclax, a Bcl2 Inhibitor with Safety Improvements

                            Details : ZE50-0134 (eiletoclax) is a highly potent and selective BCL2 inhibitor. It is being evaluated in phase 1 tirals for the treatment of acute myeloid leukemia & chronic lymphocytic leukemia.

                            Product Name : ZE50-0134

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            January 29, 2024

                            Lead Product(s) : Eiletoclax

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Eilean Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed

                            Eilean Therapeutics

                            U.S.A arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lomonitinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Eilean Therapeutics Doses First Patient with ZE46-0134, A Selective FLT3WT-Sparing, Pan FLT3Mut Inhibitor

                            Details : ZE46-0134, a highly potent and selective pan-FLT3 inhibitor that targets clinically relevant FLT3 mutations including the FLT3 gatekeeper mutation, while sparing the wild type form of the protein.

                            Product Name : ZE46-0134

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 21, 2023

                            Lead Product(s) : Lomonitinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth